Regulation of albumin and alpha-fetoprotein gene expression
白蛋白和甲胎蛋白基因表达的调节
基本信息
- 批准号:04670437
- 负责人:
- 金额:$ 0.58万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for General Scientific Research (C)
- 财政年份:1992
- 资助国家:日本
- 起止时间:1992 至 1993
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Albumin and Alpha-fetoprotein (AFP) genes are tandemly arranged on human chromosome 4. However, the regulation of both genes is reciprocal after birth. In fact, AFP gene expression decreases to an almost undetectable level after birth ; in contrast, albumin gene expression remains high throughout life. The AFP gene is re-expressed in human hepatoma cells.In this study, the regulation of albumin and AFP genes by colloid osmotic pressure (COP), hepatocyte growth factor (HGF) and butyrate was analyzed using Northern blotting and CAT plasmid transfection assay. COP down-regulated both genes through the suppression of their promoter activities. HGF also repressed the AFP promoter activity, resulting in reduction of AFP mRNA level in a dose-dependent manner.Butyrate, a natural fermentation product of nomal colonic flora, inhibited cell growth in human hepatoma cells. Butyrate up-regulated the albumin gene expression, whereas it down-regulated the AFP gene expression through the modulation of their poromoter activities. Thus, it is possible that butyrate acts as a differentiation-inducer via the portal blood flow in human hepatoma cells.
白蛋白和甲胎蛋白(AFP)基因串联排列在人类4号染色体上。然而,这两种基因的调节在出生后是相互的。事实上,AFP基因表达在出生后降低到几乎检测不到的水平;相反,白蛋白基因表达在整个生命中保持高水平。AFP基因在人肝癌细胞中重新表达,本研究采用北方印迹法和CAT质粒转染法分析胶体渗透压(COP)、肝细胞生长因子(HGF)和丁酸盐对AFP基因和白蛋白基因表达的调控。COP通过抑制它们的启动子活性来下调这两个基因。丁酸盐是正常结肠植物群的天然发酵产物,能抑制人肝癌细胞的生长。丁酸通过调节促孔剂活性上调白蛋白基因表达,而下调AFP基因表达。因此,丁酸可能通过门脉血流在人肝癌细胞中起分化诱导剂的作用。
项目成果
期刊论文数量(76)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Takuya Tsutsumi: "Regulation of albumin and alpha-fetoprotein gene expression by colloid osmotic pressure in human hepatoma cells" Gastroenterology. 104. 256-262 (1993)
Takuya Tsutsumi:“人肝癌细胞中胶体渗透压对白蛋白和甲胎蛋白基因表达的调节”胃肠病学。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Takuya Tsutsumi: "Regulation of albumin and α-fetoprotein gene expression by colloid osmotic pressure in human hepatoma cells" Gastroenterology. 104. 256-262 (1993)
Takuya Tsutsumi:“人肝癌细胞中胶体渗透压对白蛋白和甲胎蛋白基因表达的调节”胃肠病学。 104. 256-262 (1993)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Masahiko Hatano: "Hepatocyte growth factor down-regulates the α-fetoprotein gene expression in PLC/PRF/5 human hepatoma cells" Biochemical and Biophysical Research Communications. 189. 385-391 (1992)
Masahiko Hatano:“肝细胞生长因子下调 PLC/PRF/5 人肝癌细胞中的甲胎蛋白基因表达”《生物化学和生物物理研究通讯》189. 385-391 (1992)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Keisuke Nakata: "A possible mechanism of inverse developmental regulation of α-fetoprotein and albumin genes" Journal of Biological Chemistry. 267. 1331-1334 (1992)
Keisuke Nakata:“甲胎蛋白和白蛋白基因逆向发育调控的可能机制”《生物化学杂志》267. 1331-1334 (1992)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Keisuke Nakata: "Transcatheter arterial embolization of hepatic neoplasms" Critical Reviews in Oncology and Hematology. 13. 93-105 (1992)
Keisuke Nakata:“肝肿瘤的经导管动脉栓塞”肿瘤学和血液学评论。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAKATA Keisuke其他文献
NAKATA Keisuke的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAKATA Keisuke', 18)}}的其他基金
Gene therapy for hepatocellular carcinoma using an endogenous antineoangiogenetic factor, angiostatin
使用内源性抗血管生成因子血管抑制素对肝细胞癌进行基因治疗
- 批准号:
11670513 - 财政年份:1999
- 资助金额:
$ 0.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of alpha-fetoprotein silencer and analysis of its regulatory mechanisms
甲胎蛋白沉默子的鉴定及其调控机制分析
- 批准号:
09670558 - 财政年份:1997
- 资助金额:
$ 0.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Diabetes preventive function of cereal albumin considering gendered innovations
考虑性别创新的谷物白蛋白的糖尿病预防功能
- 批准号:
23K05099 - 财政年份:2023
- 资助金额:
$ 0.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CAREER: Developing albumin-binding responsive polypeptides for nucleic acid delivery
职业:开发用于核酸递送的白蛋白结合响应性多肽
- 批准号:
2238812 - 财政年份:2023
- 资助金额:
$ 0.58万 - 项目类别:
Continuing Grant
ALbumin To Enhance Recovery after severe Acute Kidney Injury (ALTER-AKI): a multicentre randomized controlled trial.
白蛋白促进严重急性肾损伤后的恢复 (ALTER-AKI):一项多中心随机对照试验。
- 批准号:
489100 - 财政年份:2023
- 资助金额:
$ 0.58万 - 项目类别:
Operating Grants
Development of albumin-binding fatty acid-modified nanoparticles for effective cancer therapy
开发用于有效癌症治疗的白蛋白结合脂肪酸修饰纳米颗粒
- 批准号:
23K06077 - 财政年份:2023
- 资助金额:
$ 0.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of albumin pre-coating DLC coated artificial vascular graft
白蛋白预涂DLC涂层人工血管的研制
- 批准号:
23K08236 - 财政年份:2023
- 资助金额:
$ 0.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
- 批准号:
10522591 - 财政年份:2022
- 资助金额:
$ 0.58万 - 项目类别:
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
- 批准号:
10884052 - 财政年份:2022
- 资助金额:
$ 0.58万 - 项目类别:
Albumin hitchhiking siRNAs for gene targeting in aged brain
白蛋白搭便车 siRNA 用于老年大脑基因靶向
- 批准号:
10611521 - 财政年份:2022
- 资助金额:
$ 0.58万 - 项目类别:
Albumin hitchhiking siRNAs for gene targeting in aged brain
白蛋白搭便车 siRNA 用于老年大脑基因靶向
- 批准号:
10467737 - 财政年份:2022
- 资助金额:
$ 0.58万 - 项目类别:
Albumin-binding nanocomplexes for delivery of combination siRNA therapeutics to KRAS-driven cholangiocarcinoma
白蛋白结合纳米复合物用于向 KRAS 驱动的胆管癌递送组合 siRNA 疗法
- 批准号:
10389971 - 财政年份:2022
- 资助金额:
$ 0.58万 - 项目类别: